Isotopic Tracer Techniques In Preclinical Research

This book serves as a practical guide and a manual on the application of isotopic tracers in understanding the cellular processes (e.g. molecular interactions, protein synthesis) in growth, development, and disease conditions. The techniques described in the book have been carefully chosen to underscore the role and relevance of isotopic tracers in the identification of molecular targets and mechanisms, and preclinical validation of potential therapeutics. This book is intended to be a valuable resource to non-experts that may include students, researchers, educators/teachers, and others who have an interest to understand the application of isotopic tracers in research. Each chapter includes a background, an outline of the method and underlying principles, and a detailed step-wise protocol. To augment the clarity and intellectual grasp, the chapters also include relevant illustrations and study questions. More importantly, the book covers techniques involving radioactive as well as non-radioactive tracers to expand the scope of isotopes in preclinical research including basic and applied science.

This book aims to aid the selection of the most appropriate methods for use in early phase (1 and 2) clinical studies of new drugs for diabetes, obesity, non-alcoholic fatty liver disease (NAFLD) and related cardiometabolic disorders. Clinical research methods to assess the pharmacokinetics and pharmacodynamics of new diabetes drugs, e.g. the euglycemic clamp technique, have become well-established in proof-of-mechanism studies. However, selection of the most appropriate techniques is by no means straightforward. Moreover, the application of such methods must conform to the regulatory requirements for new drugs. This book discusses the need for new pharmacotherapies for diabetes, obesity and NAFLD and the molecular targets of drugs currently in development. Emerging technologies including functional imaging, circulating biomarkers and omics are considered together with practical and ethical issues pertaining to early phase clinical trials in subjects with cardiometabolic disorders. Translational Research Methods in Diabetes, Obesity, and Non-Alcoholic Fatty Liver Disease is of interest to biomedical scientists, pharmacologists, academics involved in metabolic research and clinicians practicing in these specialties.

The world is beset by a pandemic of obesity and type 2 diabetes and the need for new drugs is startlingly clear; recent years have seen a huge increase in research activity to fill this gap. The development of new drugs for diabetes and obesity must be founded upon a sound appreciation of the pathophysiology of these common disorders. The dual defects of insulin resistance and impaired insulin secretion are fundamental to the pathogenesis and progression of obesity-associated type 2 diabetes. There is a need to explain how new drugs can counter insulin resistance and insulin deficiency to a broad range of professionals, from clinical scientists active in early (and later) phase drug development to specialist physicians and increasingly primary care doctors who must tailor drug regimens to the individual patient. Clinical research methods for measuring insulin action and insulin secretion have become well-established in proof-of-mechanism studies; however, selection of the best techniques is by no means straightforward. The purpose of the book is to aid the selection of the most appropriate techniques for assessing insulin action, insulin secretion and body composition in humans (with particular reference to new drugs) in phase 1 and 2 studies and aid the understanding of drug effects and non-drug treatment strategies on key biochemical-hormonal defects of obesity and type 2 diabetes. The book will assume a working knowledge of human physiology relating to glucose metabolism and will be of interest to biomedical scientists, pharmacologists, academics involved in metabolic research and clinicians practicing in these specialties.

With perspectives from academia and industry across a spectrum of techniques, this is a go-to volume for biophysicists, analytical chemists and medicinal chemists looking for a broad overview of techniques of contemporary interest in drug discovery.

Animal cell technology has undergone a rapid transformation over the last decade from a research tool and highly specialised technology to a central resource for innovation in pharmaceutical research and development. These proceedings of the 14th Meeting of the European Society for Animal Cell Technology (Vilamoura, Portugal, May 1996) bring up to date the historical perspective of animal cell technology for the benefit of society, `From Vaccines to Genetic Medicine', and will charter this vital technology for the years to come. Strong contributions are grouped in the traditional ESACT areas of 'Cell and Physiology Engineering' dealing with cell state, including genetics, and its environment, and 'Animal Cell Process Engineering' covering integration of bioreaction with bioseparation coupled with on-line monitoring to improve protein production and consistency. Extensive coverage of metabolic engineering on synthesis, folding, assembly, transiting and secretion is dealt with in the session on 'Recombinant Proteins: Biosynthesis and Bioprocessing'. Two traditional but expanding areas of animal cell technology relevance are highlighted in the broad sessions of 'Animal Cells as Tools for Discovery and Testing' and 'Animal Cell Vaccines: Present and Future'. Two sessions finally cover the more recent domains of animal cell technology work - 'Tissue Engineering and Biomedical Devices' and 'Cells and Vectors for Genetic Medicine' - where one can foresee a very bright future.